A Medical Device Daily Staff Report
BioImagene (Sunnyvale, California) reported a collaboration with the University of Kansas Medical Center (KUMC; Kansas City, Kansas) Department of Pathology & Laboratory Medicine to develop companion algorithms for next-generation companion diagnostics for digital pathology. Under the terms of the collaboration, researchers from KUMC and BioImagene will work together to develop new companion algorithms for DNA Ploidy analysis and other tumor markers, including breast, colon and gynecologic. Researchers and clinicians from KUMC will also utilize BioImagene's iScan Coreo AU slide scanner and Virtuoso digital pathology software to digitize samples and collaborate on development and validation of algorithms for diagnostic use.
"The era of pharmacodiagnostics has expanded the pathologist's role of 'chief diagnostician,' with HER2 providing pathologists with many lessons on optimal assessment of biomarkers to help qualify patients for individualized therapies," said Ossama Tawfik, MD, PhD, professor and Vice-Chair of Education and Outreach, and Director, Anatomic & Surgical Pathology at the University of Kansas Department of Pathology & Laboratory Medicine. "KUMC looks forward to partnering with BioImagene to advance digital pathology and help pathologists and researchers transition from traditional microscopes to digitized images, which will further standardize interpretation and improve accuracy and efficiency."
"Digital Pathology is a highly disruptive innovation. That makes it more important than ever for the pioneers in the industry to work with academic thought leaders. That's the only way to ensure that the full potential of this innovation will be realized quickly, and adopted widely. Ultimately, this will lead to improved quality and efficiency of diagnosis and better outcome for the patient," said Ajit Singh, PhD, CEO of BioImagene. "This collaboration between BioImagene and University of Kansas Medical Center is an important milestone for us, and will go a long way in making our vision of personalized medicine a reality."